Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE

NCT ID: NCT07235410

Last Updated: 2025-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-11-01

Study Completion Date

2026-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatocellular carcinoma (HCC) is a common liver cancer, and many patients cannot receive surgery. For these patients, transarterial chemoembolization (TACE) is an important treatment. However, patients often respond differently to TACE, and it is difficult to predict who will benefit most. This study uses deep learning to automatically analyze routine CT images taken before TACE. By measuring body composition features, such as the size and condition of different abdominal organs and tissues, we aim to better understand patients' overall health status and treatment tolerance. The goal is to develop a prediction model that can help doctors estimate survival and treatment outcomes more accurately. This may assist in making more personalized treatment decisions and improving patient care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients diagnosed with "Hepatocellular Carcinoma" from January 1, 2018 to May 31, 2024;
2. Age \> 18 years old.

Exclusion Criteria

1. Poor image quality;
2. Loss of follow-up;
3. Presence of another type of malignant tumor other than liver cancer;
4. Incomplete medical records.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lian Yang

Archiater

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yuanyuan Chu

Role: CONTACT

+8602785726375

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yi Li

Role: primary

+8617364176403

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

[2025](1186)

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.